Literature DB >> 3651385

Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione.

A Eastman1, M A Barry.   

Abstract

Bifunctional reactions with DNA are responsible for the toxic action of the cancer chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-DDP). Thiourea has previously been used to trap transient monofunctional adducts in DNA before they rearrange to the toxic lesions. In these studies, thiourea was used to quantify the monofunctional adducts produced by the ineffective isomer trans-DDP. Rather than trapping monofunctional adducts, thiourea labilized them from DNA. At short time periods, 85% of trans-DDP bound to double-stranded DNA as monofunctional adducts of deoxyguanosine. Rearrangement to bifunctional adducts in double-stranded DNA was 50% complete in 24 h but was much more rapid in single-stranded DNA with 100% complete rearrangement in 24 h. The ineffectiveness of trans-DDP therefore results from a high proportion of monofunctional adducts in DNA that rearrange very slowly to toxic bifunctional adducts. The persistent monofunctional adducts react rapidly with glutathione, which would further reduce their potential toxicity by preventing them from rearranging to more toxic bifunctional adducts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3651385     DOI: 10.1021/bi00386a009

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  32 in total

Review 1.  Formation and repair of interstrand cross-links in DNA.

Authors:  David M Noll; Tracey McGregor Mason; Paul S Miller
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

2.  Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand.

Authors:  Yousef Najajreh; Jana Kasparkova; Victoria Marini; Dan Gibson; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2005-11-08       Impact factor: 3.358

3.  Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).

Authors:  W I Sundquist; S J Lippard; B D Stollar
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione.

Authors:  K Lemma; J Berglund; N Farrell; L I Elding
Journal:  J Biol Inorg Chem       Date:  2000-06       Impact factor: 3.358

5.  DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

Authors:  V Brabec; O Vrána; O Nováková; V Kleinwächter; F P Intini; M Coluccia; G Natile
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

6.  Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II).

Authors:  J Hansson; R D Wood
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

7.  Biophysical studies on the stability of DNA intrastrand cross-links of transplatin.

Authors:  Jana Kasparkova; Victoria Marini; Vendula Bursova; Viktor Brabec
Journal:  Biophys J       Date:  2008-08-01       Impact factor: 4.033

8.  A potent cytotoxic photoactivated platinum complex.

Authors:  Fiona S Mackay; Julie A Woods; Pavla Heringová; Jana Kaspárková; Ana M Pizarro; Stephen A Moggach; Simon Parsons; Viktor Brabec; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-19       Impact factor: 11.205

9.  DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)-modified DNA.

Authors:  R Dalbiès; D Payet; M Leng
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

10.  DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.

Authors:  Olga Novakova; Jana Kasparkova; Jaroslav Malina; Giovanni Natile; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.